Investors Said That The Market Prospect Of Domestic Sphygmomanometers Is Promising With The Continuous Promotion Of Chronic Disease Health Management

As mercury sphygmomanometer gradually retired from the market, electronic sphygmomanometer entered the era of home.

Ruiguang Kangtai is a high-tech comprehensive medical device manufacturer engaged in medical device R & D, production, sales and chronic disease health management. Its products mainly cover the new generation of pulse wave sphygmomanometer, health examination all-in-one machine, laser medical equipment, blood pressure and chronic disease cloud health management system, identification integrated management system and other products.

It is worth mentioning that Ruiguang Kangtai's pulse wave sphygmomanometer has independently developed the fourth generation accurate blood pressure measurement technology - pulse wave blood pressure measurement method, which has obtained invention patents from many countries around the world. It is reported that the accuracy is as high as ± 2mmhg, far higher than the national standard of ± 5mmhg.

This year, Ruiguang Kangtai completed the 55 million B + round of financing from Dongfang Fuhai leading investment. In this regard, Zhang Zhixing, the investment director of Dongfang Fuhai, told the reporter of the 21st century economic report that Ruiguang Kangtai's exclusive technology has been recognized by the industry, and has established a strategic cooperation relationship with domestic well-known intelligent hardware giants, hoping that in the future, Ruiguang Kangtai will have the opportunity to enter the capital market like the gem.

Liu Wenjun, angel investor and general manager of Veritas investment, said that the main reasons for investment in Ruiguang Kangtai were the advanced technology and excellent leadership team of the company and the broad prospects of the industry in which the company was located.

The market of sphygmomanometer increases greatly

In recent years, more and more attention has been paid to the prevention and management of chronic diseases, and the early prevention of diseases has been paid more and more attention.

According to the "healthy China 2030" planning outline released by the CPC Central Committee and the State Council in 2016, it is necessary to implement the comprehensive prevention and control strategy of chronic diseases and strengthen the construction of national demonstration area for comprehensive prevention and control of chronic diseases. We will strengthen the screening and early detection of chronic diseases, carry out early diagnosis and treatment for key cancers in high-risk areas, and promote the opportunistic screening of chronic diseases such as cancer, stroke and coronary heart disease. We will basically achieve the full coverage of management and intervention for patients with hypertension and diabetes, and gradually bring the appropriate technologies for early diagnosis and treatment of major chronic diseases such as cancer and stroke into the routine diagnosis and treatment.

In China, hypertension is a common chronic disease. In this regard, Zhang Zhixing confessed to the reporter that the investment depends on the trend, and the investment in Ruiguang Kangtai is also based on this logic. In terms of hypertension, the specific choice is the subdivision track of hypertension diagnosis.

In fact, sphygmomanometer is not a new product. From mercury sphygmomanometer to electronic sphygmomanometer, sphygmomanometer may have a history of hundreds of years.

In fact, although the accuracy of mercury sphygmomanometer is high, it has been gradually eliminated due to the serious environmental pollution.

Notice on the implementation of the Convention issued by the State Administration of Medicine on October 14. The notice pointed out that the drug administration of all provinces, autonomous regions, municipalities directly under the central government and Xinjiang production and construction corps should attach great importance to it and guide relevant enterprises in their jurisdiction to ban the production of mercury containing thermometers and mercury containing sphygmomanometers from January 1, 2026.

It is worth mentioning that the Convention is an environmental protection treaty jointly signed by 128 contracting parties under the leadership of the United Nations, and has entered into force in China as early as August 16, 2017.

Mercury, commonly known as mercury, is highly toxic and has been listed as one of the top ten chemicals endangering human health and environment by the United Nations. Inhalation of mercury vapor may cause harm to respiratory system and central nervous system, and ingestion of mercury containing food may lead to Minamata disease.

When mercury sphygmomanometer was launched into the market, the market space left by it was transferred to the electronic sphygmomanometer. Therefore, the market of electronic sphygmomanometer has a large space for growth, with an annual growth rate of about 20%.

Zhang Zhixing mentioned that after the "dual cycle" development strategy was determined by the state, it also provided a large market space for domestic electronic sphygmomanometers. Although electronic sphygmomanometer is a common thing, imported brands still occupy more than half of the market share. If the domestic sphygmomanometer can replace the imported sphygmomanometer, the accuracy is the key. The advantage of Ruiguang Kangtai's sphygmomanometers is accuracy, because they have a unique pulse wave measurement method, which avoids the inaccuracy of measurement results for special groups of people.

"In addition to being used in hospitals, sphygmomanometers will definitely go to families in the future, and their market space will be further opened. After more than ten years of technical precipitation, the pulse wave electronic blood pressure meter invented by Dr. Wu Xiaoguang of Ruiguang Kangtai company has almost no difference with the traditional mercury sphygmomanometer in accuracy and stability. " Liu Wenjun thinks.

Internet + blood pressure management

Since this year, due to the impact of the new epidemic, Internet hospitals play an important strategic role, and make more patients realize and experience the convenience of Internet hospitals. The "Internet + medical health" model is gradually gaining popularity.

On April 28, 2018, the general office of the State Council issued the opinions on promoting the development of "Internet + medical health" (hereinafter referred to as the "opinions"). According to the opinion, we should improve the "Internet + medical and health" service system, including the development of "Internet +" medical services and innovation of "Internet +" public health services; improve the "Internet + medical health" support system, including accelerating the realization of medical and health information sharing, improving the "Internet + medical health" standard system, and improving hospital management and convenient service level Etc.

Ruiguang Kangtai is also actively exploring the solution of "Internet + blood pressure management", which has the following functions: integrating multiple parameters of hospital community family to objectively reflect the patient's disease status; establishing doctor-patient communication, online and offline patient education, intelligent reminder and follow-up mechanism; participating in the construction of specialized clinical research public service platform and disease collaborative research network; the management system enables scientific research data Multi center data sharing facilitates large-scale clinical research and optimizes the management mechanism of clinical research.

At the same time, with the implementation of the hierarchical diagnosis and treatment system, Ruiguang Kangtai has strengthened the layout of the community and promoted remote diagnosis and treatment. Zhang Zhixing told reporters that by putting blood pressure meters and blood glucose meters in the community, we can complete the long-term monitoring of diabetes and hypertension population, and complete the screening of hypertension population in the community. After screening, we can complete remote contact with the doctors of grade III and grade A hospitals through the information system, so that these doctors can further screen out high-risk patients, and transfer them to higher level hospitals or tertiary hospitals as appropriate, so as to reduce the pressure of grade III hospitals.

"If we can do it in the future, we can accurately screen out the hypertension population in China. Ruiguang Kangtai is also vigorously promoting relevant products to the community. On the whole, what Ruiguang Kangtai has done is a very meaningful thing. In terms of mastering independent and controllable core technologies, Ruiguang Kangtai is also a very valuable enterprise. " Zhang Zhixing said.

Liu Wenjun added that at present, Ruiguang Kangtai's products have been widely recognized in the market, and the brand awareness has gradually increased. I believe that the company will become the industry leader in the future.